Thursday, December 3rd, 2020
Ralph DeFronzo, MD
Fatty Kidney: The Renal Manifestation of the Metabolic Syndrome
Kenneth Cusi, MD
Nonalcoholic Fatty Liver Disease and Diabetes: Clinical Implications of "Foie Gras"
Eric Ravussin, PhD
The Beta Cell- Insulin Resistance Connection: A Fat Story
Martha Gulati, MD
Sex Differences in Coronary Artery Calcium and Long-Term CV Mortality
Gina P. Lundberg, MD
Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women
Howard Hodis, MD
Hormone Replacement Therapy, Atherosclerosis and Cardiovascular Disease: An Update
Geltrude Mingrone,MD
Obesity and Metabolic Surgery During and Beyond COVID-19
Derek LeRoith, MD, PhD
Overview of The Interaction Between Obesity, Diabetes and Cancer Therapy
Emily Gallagher, MD, PhD
The Effect of Tyrosine Kinase, PI3K/mTor Inhibitors on Metabolism
Richard Bergman, PhD
Important Role of Reduced Insulin Clearance in Pathogenesis of Type 2 Diabetes: Hypothesis and Experimental Confirmation in Man
Maria Rosa Costanzo, MD
Epidemiology and Traditional Management of HF and CKD
Mikhail Kosiborod, MD
The Future Is Here: Contemporary Approach to HF with a Focus on HFrEF
Katherine Tuttle, MD
Revolution in the Management of Moderate to Severe CKD
Muthiah Vaduganathan, MD
Impact of Recent CVOTs on Contemporary Guidelines for HF and CKD
CME Satellite Symposium:
Heart Failure and Kidney Disease: The Next Epidemics
Supported by AstraZeneca
Friday, December 4th, 2020
Aaron Kelly, PhD
The Ceramide Pathway as a Target for Insulin Sensitization
Thomas Inge, MD, PhD
Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults
Sonia Caprio, MD
Sleeve Gastrectomy Impact on Cell Size and Genes from Adipose Tissue of Obese Adolescent Girls
Philipp Scherer, PhD
The Ceramide Pathway as a Target for Insulin Sensitization
Gerald Shulman, MD, PhD
Diacylglycerols and acetyl-CoA as a Therapeutic Targets for Insulin Resistance and Type 2 Diabetes
Robert Rosenson, MD
Triglycerides and CVD: Causal or Coincidental? Lessons from Recent Research
Norman Lepor, MD
The Role of LP(a) & ANGPTL3 in Lipids Atherosclerosis and Cardiovascular Disease
Ronald Evans, PhD
Stem Cell Generated Human Islets- Rescue Diabetes Without a Device
Gerald Watts, MD
Go with the Flow: Understanding Lipid Metabolism with Tracer Methods
Michael Snyder, PhD
Multiomics Analysis of IR vs IS Responses to Viral Infections, Exercise and Aging
Tracey McLaughlin, MD
Continuous Glucose Monitoring for Precision Diets
Jerome Rotter, MD
The Genetic Interrelationship Between T2D & Coronary Heart Disease
Christos Mantzoros, MD, PhD
NASH- The Status of Diagnostics and Therapeutics
Bart Staels, PhD
The Sexually Dimorphic Nature of NASH May Impact on Disease Progression and Responses To Drugs
Jorge Plutzky, MD
Anti-Inflammatory Impact on Atherosclerosis: CVOT and Management Implications
Matthew Budoff, MD
Impact of Non Statin Drugs On Plaque Formation and Atherosclerosis
Kevin Hall, PhD
The Influence of Dietary Carbs, Fat, And Quality on Ad Libitum Calorie Intake
W. Timothy Garvey, MD
Future of Obesity Pharmacotherapy: New Drugs and New Targets
Samuel Klein, MD
Does Intestinal Bypass Surgery Really Have Weight-Loss-Independent Therapeutic Metabolic Effects?
Peter A. McCullough, MD
Pathophysiological Basis & Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
Ajay Nirula, MD, PhD
The Role of Neutralizing Antibody Therapy in the Management of COVID-19
Deepak Bhatt, MD
Primary and Secondary Prevention of CVD – Current standard of Care
Neha Pagidipati, MD
High TGL association with ASCVD- Epidemiology and pathophysiology
CME Satellite Symposium:
Emerging Standard of Care in the Prevention of Cardiovascular Morbidity and Mortality
Supported by Amarin
Sunday, December 6th, 2020
Peter Grant, MD
Insulin Resistance And Thrombotic Risk: Implications For Therapeutic Approaches To Vascular Disease
Brendan Everett, MD
The ACC’s Expert Consensus Decision Pathway: Improving Cardiovascular Outcomes in Type 2 Diabetes
Mikhail N. Kosiborod, MD
The Future of Cardiometabolic Care is Here: Announcing Cardiometabolic Center Alliance
Francesco Giorgino, MD
Managing Type 2 Diabetes to Prevent CVD-CKD: SGLT-2i, GLP-1RA or Initial Combination of Both?
Robert Eckel, MD
The Current Management of CV Risk factors in Type 1 Diabetes
Richard Pratley, MD
DEBATE: Should T2D Medications with Proven CV Benefits be Used in T1D to Prevent ASCVD: Yes
David Nathan, MD
Why Using T2D Medications with CVD Benefits is a Bad Idea for Type 1 Diabetes
David Cherney, MD
GLP1-RA and SGLT2i in the Treatment of Diabetic Nephropathy: What Does the Future Hold?
Monica Aggarwal, MD
Lifestyle Modifications for Preventing and Treating Heart Failure
Javed Butler, MD
Update on HFOT impact on Management - Sequencing vs Initial Combination of Medication